PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

PEGS Boston – 17/02/2025
NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

A Look to Lessons Past: Why Biopharma Should Make Use of Small Molecule Expertise

The past decade has seen unprecedented growth in the biopharmaceutical industry, with the global compound annual growth rate (CAGR) estimated to reach 8.5% between 2017 and 2023. Fuelled by R&D successes which introduce new drug classes such as checkpoint inhibitors, viral gene therapies and antibody drug conjugates to the market, this growth is now threatening to overwhelm the industry. Rutger Oudejans Brand Director at bioLIVE, UBM explores solutions to these problems –namely taking lessons from issues faced by the small molecule industry 20 years ago.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/10/A-look-to-lessons-past_why-biopharma.pdf” width=”100%” height=”900px” style=”border:0;”]

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40